González-Becerra JE, Moreno-García JD, Sondón-García ZG, Regalado-Hernández MA

Language: Spanish
References: 22
Page: 440-447
PDF size: 526.65 Kb.

ABSTRACT

Background: Ovarian stimulation is a key component in assisted reproduction techniques. Supraphysiologic levels secondary to hormonal stimulation with high doses of exogenous hormones affect endometrial receptivity, the function of the corpus luteum, ovulation and embryo quality. The use of stimulation protocols called “minimal stimulation” may have a beneficial effect in achieving pregnancy.
Objectives: To evaluate the clinical efficacy (pregnancy rate) of rLH treatment on Day 5 (minimum group “A”) vs. Day 8 (minimum group “B”) of the ovarian stimulation cycle.
Material and Methods: Cohort, retrospective, pilot study. Two groups of 22 patients each who received minimal stimulation “A” or “B” (control group) in the period from April to August 2010.
Results: No statistically significant difference in the following variables: age, FSH, estradiol and basal follicles. The median of mature follicles at the shooting day, the minimum group “A” was 3 vs. 2 for low B, the number of oocytes at metaphase II: Minimum group “A” 37/65 (57%) vs. 24/38 (63 %) at minimal group “B”. Patients with grade 1+ quality embryos were 7 in minimal group “A” vs. 6 in the minimal group “B”. In the minimal group “A”, the pregnancy rate per started cycle was 27.3% and 37.5% for transfer, in the minimal group “B”, the pregnancy rate per started cycle was 22.7% and per patient transfer which underwent 25%.
Conclusions: Receiving the minimal stimulation protocol “A” has a 15% higher risk of becoming pregnant, compared with minimal group “B” based on pregnancy rate per transfer, for the sample size, the p value was 0.32.

REFERENCES

1. Matorras R. Epidemiología de la esterilidad. Actualizaciones de la Sociedad Española de Fertilidad. Sociedad Española de Fertilidad 2000; 7-9.

2. Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005;365:1807-1816.

3. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006;27:170-207.

4. Van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993;8:369-373.

5. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-577.

6. Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996;11:917-919.

7. Diedrich K, Ferberbaum F. New approaches to ovarian stimulation. Hum Reprod 1998;13(Suppl. 3):1-13.

8. Short RV. Steroids in the follicular fluid and the corpus luteum of the mare. A ‘two-cell type’ theory of ovarian steroid synthesis. J Endocrinol 1962;24:59-63.

9. Hull M, Corrigan E, Piazzi A, Loumaye E. Recombinant human luteinizing hormone: an effective new gonodotropin preparation. Lancet 1994;344(8918):334-335.

10. Ganirelix Dose-Finding Study Group. A double-blind randomized, dose-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist ganirelix to prevent premature LH surges in women undergoing ovarian stimulation with recombinant FSH. Human Reproduction 1998;13:3023-31.

11. Levy DP, Navarro JM, Schattman G, Davis OK, Rosenwaks Z. The role of LH in ovarian stimulation. Human Reproduction 2000;15:2258-65.

12. Mitwally M, Casper R. Use of an aromatase inhibitor for ovulation induction in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75:305-309.

13. Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004;82:1561-1563.

14. Biljan M, Tan SL, Tulandi T. Prospective randomized trial comparing letrozole at 2.5 and 5.0 mg on follicular development, endometrial thickness and pregnancy rate in patients undergoing superovulation. Fertil Steril 2002;78:S55.

15. Mitwally M, Casper R. Aromatase inhibition reduces the gonadotropin dose for ovarian stimulation in unexplained infertility patients. Hum Reprod 2003;18:1588-97.

16. Mitwally M, Casper R. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian stimulation. J Soc Gynecol Investig 2004;11:406-15.

17. Goswami SK, Das T, Chattopadhyay R, Sawhney V, Kumar J, Chaudhury K, et al. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod 2004;19:2031-5.

18. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003;18:1588-97.

19. Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2006;91:760-71.

20. Garcia-Velasco JA, Moreno L, Pacheco A, Guillen A, Duque L, Requena A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005;84:82-7.

21. Hohmann F, Macklon N, Fauster B, et al. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulation hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003;88;166-173.

22. Baart E, Martini E, Eijikemans M, et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007;22:980-988.